Cargando…
Von Hippel-Lindau Disease and the Eye
Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign lesion originating from the endothelial and glial components of the neurosensory retina and optic nerve head. Historically known as a manifestation of the von Hippel-Lindau (VHL) disease, it can be seen as an iso...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PUBLISHED BY KNOWLEDGE E
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001024/ https://www.ncbi.nlm.nih.gov/pubmed/32095212 http://dx.doi.org/10.18502/jovr.v15i1.5950 |
_version_ | 1783494156790792192 |
---|---|
author | Karimi, Saeed Arabi, Amir Shahraki, Toktam Safi, Sare |
author_facet | Karimi, Saeed Arabi, Amir Shahraki, Toktam Safi, Sare |
author_sort | Karimi, Saeed |
collection | PubMed |
description | Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign lesion originating from the endothelial and glial components of the neurosensory retina and optic nerve head. Historically known as a manifestation of the von Hippel-Lindau (VHL) disease, it can be seen as an isolated finding or in association with some rare ocular conditions. In addition to characteristic ophthalmoscopic features, results of numerous ancillary tests including angiography, ultrasound, optical coherence tomography, and genetic tests may support the diagnosis and differentiate it from similar conditions. Because of serious life-threatening complications of VHL disease, every ocular approach to retinal hemangioblastomas should be in relationship with additional multidisciplinary diagnostic and therapeutic efforts. In addition, any patient with actual or probable diagnosis of VHL disease should be screened for ocular involvement. Unfavorable visual loss can occur early, and ocular complications of VHL range from exudative retinopathy to tractional retinal detachment, neovascular glaucoma, and phthisis bulbi. Accordingly, various treatment methods have been tested with overall acceptable responses, including photocoagulation, cryotherapy, photodynamic therapy, plaque radiotherapy, vitrectomy, and more novel intravitreal injections of anti-vascular endothelial growth factors and propranolol. |
format | Online Article Text |
id | pubmed-7001024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | PUBLISHED BY KNOWLEDGE E |
record_format | MEDLINE/PubMed |
spelling | pubmed-70010242020-02-24 Von Hippel-Lindau Disease and the Eye Karimi, Saeed Arabi, Amir Shahraki, Toktam Safi, Sare J Ophthalmic Vis Res Review Article Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign lesion originating from the endothelial and glial components of the neurosensory retina and optic nerve head. Historically known as a manifestation of the von Hippel-Lindau (VHL) disease, it can be seen as an isolated finding or in association with some rare ocular conditions. In addition to characteristic ophthalmoscopic features, results of numerous ancillary tests including angiography, ultrasound, optical coherence tomography, and genetic tests may support the diagnosis and differentiate it from similar conditions. Because of serious life-threatening complications of VHL disease, every ocular approach to retinal hemangioblastomas should be in relationship with additional multidisciplinary diagnostic and therapeutic efforts. In addition, any patient with actual or probable diagnosis of VHL disease should be screened for ocular involvement. Unfavorable visual loss can occur early, and ocular complications of VHL range from exudative retinopathy to tractional retinal detachment, neovascular glaucoma, and phthisis bulbi. Accordingly, various treatment methods have been tested with overall acceptable responses, including photocoagulation, cryotherapy, photodynamic therapy, plaque radiotherapy, vitrectomy, and more novel intravitreal injections of anti-vascular endothelial growth factors and propranolol. PUBLISHED BY KNOWLEDGE E 2020-02-02 /pmc/articles/PMC7001024/ /pubmed/32095212 http://dx.doi.org/10.18502/jovr.v15i1.5950 Text en Copyright © 2020 Karimi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Review Article Karimi, Saeed Arabi, Amir Shahraki, Toktam Safi, Sare Von Hippel-Lindau Disease and the Eye |
title | Von Hippel-Lindau Disease and the Eye |
title_full | Von Hippel-Lindau Disease and the Eye |
title_fullStr | Von Hippel-Lindau Disease and the Eye |
title_full_unstemmed | Von Hippel-Lindau Disease and the Eye |
title_short | Von Hippel-Lindau Disease and the Eye |
title_sort | von hippel-lindau disease and the eye |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001024/ https://www.ncbi.nlm.nih.gov/pubmed/32095212 http://dx.doi.org/10.18502/jovr.v15i1.5950 |
work_keys_str_mv | AT karimisaeed vonhippellindaudiseaseandtheeye AT arabiamir vonhippellindaudiseaseandtheeye AT shahrakitoktam vonhippellindaudiseaseandtheeye AT safisare vonhippellindaudiseaseandtheeye |